As of March 23, 2026, VYNE Therapeutics's top three insider holders are David Domzalski (President And Ceo, 416.21K shares), Mutya Harsch (Chief Legal Officer And Gc, 125.91K shares), Andrew Saik (Chief Financial Officer, 116.47K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David Domzalski | President And Ceo | 416,208 | 0 | 05 Jan, 2026 |
| Mutya Harsch | Chief Legal Officer And Gc | 125,905 | 0 | 05 Jan, 2026 |
| Andrew Saik | Chief Financial Officer | 116,468 | 0 | 02 Jun, 2021 |
| Iain Stuart | Chief Scientific Officer | 115,239 | 0 | 05 Jan, 2026 |
| Matthew T. Wiley | Chief Commercial Officer | 109,246 | 0 | 02 Jul, 2021 |
| Tyler Zeronda | Chief Financial Officer | 103,795 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Dec, 2025 | David Domzalski | Common Stock | D | 12,684 | $0.58 | 416,208 | D | F |
| 31 Dec, 2025 | Iain Stuart | Common Stock | D | 2,448 | $0.58 | 115,239 | D | F |
| 31 Dec, 2025 | Tyler Zeronda | Common Stock | D | 7,858 | $0.58 | 103,795 | D | F |
| 31 Dec, 2025 | Mutya Harsch | Common Stock | D | 3,579 | $0.58 | 125,905 | D | F |
| 12 Dec, 2025 | Elisabeth Sandoval Little | Stock Option (right to buy) | A | 20,000 | $0.00 | 20,000 | D | A |
| 30 Sep, 2025 | Iain Stuart | Common Stock | D | 2,453 | $0.34 | 117,687 | D | F |
| 30 Sep, 2025 | Mutya Harsch | Common Stock | D | 3,581 | $0.34 | 129,484 | D | F |
| 30 Sep, 2025 | Tyler Zeronda | Common Stock | D | 3,420 | $0.34 | 111,653 | D | F |
| 30 Sep, 2025 | David Domzalski | Common Stock | D | 12,676 | $0.34 | 428,892 | D | F |
| 30 Jun, 2025 | Tyler Zeronda | Common Stock | D | 3,420 | $1.65 | 115,073 | D | F |
| 30 Jun, 2025 | David Domzalski | Common Stock | D | 12,676 | $1.65 | 441,568 | D | F |
| 30 Jun, 2025 | Mutya Harsch | Common Stock | D | 3,581 | $1.65 | 133,065 | D | F |
| 30 Jun, 2025 | Iain Stuart | Common Stock | D | 2,453 | $1.65 | 120,140 | D | F |
| 02 Jun, 2025 | David Domzalski | Common Stock | A | 8,681 | $0.81 | 454,244 | D | A |
| 02 Jun, 2025 | Mutya Harsch | Common Stock | A | 1,145 | $0.81 | 136,646 | D | A |
| 31 Mar, 2025 | David Domzalski | Common Stock | D | 30,498 | $1.58 | 445,563 | D | F |
| 31 Mar, 2025 | Mutya Harsch | Common Stock | D | 8,828 | $1.58 | 135,501 | D | F |
| 31 Mar, 2025 | Tyler Zeronda | Common Stock | D | 8,399 | $1.58 | 118,493 | D | F |
| 31 Mar, 2025 | Iain Stuart | Common Stock | D | 6,044 | $1.58 | 122,593 | D | F |
| 21 Jan, 2025 | Mutya Harsch | Stock Option (right to buy) | A | 230,000 | $0.00 | 230,000 | D | A |